首页 | 本学科首页   官方微博 | 高级检索  
     


A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
Authors:Yutaka?Ogata  Mototsugu?Shimokawa  Takaho?Tanaka  Yasunori?Emi  Eiji?Oki  Hiroshi?Saeki  Noriaki?Sadanaga  Tetsuya?Kusumoto  Tetsuo?Touyama  Masami?Kimura  Hideo?Baba  Yoshito?Akagi  Kazuo?Shirouzu  Yoshihiko?Maehara  Kyushu Study Group of Clinical Cancer
Affiliation:1.Department of Surgery,Kurume University Medical Center,Kurume,Japan;2.Department of Cancer Information Research,National Hospital Organization Kyushu Cancer Center,Fukuoka,Japan;3.Department of Surgery,Social Insurance Tagawa Hospital,Tagawa,Japan;4.Department of Surgery,Saiseikai Fukuoka General Hospital,Fukuoka,Japan;5.Department of Surgery and Science,Graduate School of Medical Sciences, Kyushu University,Fukuoka,Japan;6.Department of Surgery,Nakagami Hospital,Okinawa,Japan;7.Department of Surgery,JCHO Hitoyoshi Medical Center,Hitoyoshi,Japan;8.Department of Gastroenterological Surgery,Graduate School of Medical Sciences, Kumamoto University,Kumamoto,Japan;9.Department of Surgery, Faculty of Medicine,Kurume University,Kurume,Japan
Abstract:
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号